Theragen Etex mainly engages in pharmaceutical manufacturing and sales as well as genome sequencing analysis business. The genome analysis business is divided into research areas utilizing next-generation sequencing (NGS) technology and clinical and personal genome analysis fields. It collaborates with over 650 medical institutions such as general hospitals and genome researchers and related organizations in more than 80 countries worldwide.
Patent attorney Eom Jeonghan from BLT Patent Law Firm reviewed the patent and trademark application status of Theragen Etex.
Listed companies on the domestic stock market disclose patent acquisition facts through the Financial Supervisory Service's electronic disclosure system. However, many stock investors tend to overlook patent disclosures.
Not only patents but also trademark registrations serve as important indicators for understanding future corporate value, as they signal the direction that listed companies will take. Some patent disclosures even act as direct triggers for stock price increases.
It is not easy for general investors to grasp the impact on companies through patent disclosures or to check trademark application statuses one by one. Asia Economy, together with patent attorney Eom Jeonghan from BLT Patent Law Firm, is reviewing the patent and trademark application status of listed companies through 'Teukgeup Yeolcha'.
'Teukgeup Yeolcha' is an abbreviation for a broadcast that diligently searches for rapidly rising stocks through patents.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
